Form 8-K - Current report:
SEC Accession No. 0001193125-25-129470
Filing Date
2025-05-28
Accepted
2025-05-28 16:06:12
Documents
12
Period of Report
2025-05-27
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d932298d8k.htm   iXBRL 8-K 23106
  Complete submission text file 0001193125-25-129470.txt   135982

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20250527.xsd EX-101.SCH 2836
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20250527_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20250527_pre.xml EX-101.PRE 11252
14 EXTRACTED XBRL INSTANCE DOCUMENT d932298d8k_htm.xml XML 3655
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 25995457
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)